Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition

Nature Medicine

Volumn 6, Issue 2, 2000, Pages 143-150

  Iwata, Nobuhisa ^a   Tsubuki, Satoshi ^a   Takaki, Yoshie ^a   Watanabe, Kaori ^a   Sekiguchi, Misaki ^a   Hosoki, Emi ^a   Kawashima Morishima, Maho ^b   Lee, Hahn Jun ^a   Hama, Emi ^a   Sekine Aizawa, Yoko ^a   Saido, Takaomi C ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PROTEINASE INHIBITOR; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ENZYME INHIBITOR; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CATALYSIS; CONTROLLED STUDY; HIPPOCAMPUS; MALE; METABOLIC INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REACTION ANALYSIS; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; SPRAGUE DAWLEY RAT;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; HIPPOCAMPUS; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; NEPRILYSIN; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033621739     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/72237     Document Type: Article

References (34)

1. Hardy, J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154-159 (1997).
2. Selkoe, D.J. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8, 447-453 (1998).
3. Price, D.L., Tanzi, R.E., Borchelt, D.R. & Sisodia, S.S. Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet. 32, 461-493 (1998).
4. Selkoe, D.J. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease Trends Neurosci. 16, 403-409 (1993).
5. Sisodia, S.S. & Price, D.L. Role of the β-amyloid protein in Alzheimer's disease. FASEB J. 9, 366-370 (1995).
6. Funato, H. et al. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol. 152, 1633-1640 (1998).
7. Zini, S. et al. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc. Natl. Acad. Sci. USA 93, 11968-11973 (1996).
8. O'Cuinn, G., O'Connor, B., Gilmartin, L. & Smyth, M. in Metabolism of Brain Peptides (ed. O'Cuinn, G.) 99-157 (CRC Press, Boca Raton, 1995).
9. Näslund, J. et al. High-resolution separation of amyloid β-peptides: structural variants present in Alzheimer's disease amyloid. J. Neurochem. 67, 294-301 (1996).
10. MacPherson, L.J. et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 40, 2525-2532 (1997).
11. Roques, B.P. et al. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45, 87-146 (1993).
12. Roques, B.P., Noble, F., Crine, P. & Fournie-Zaluski, M.C. Inhibitors of neprilysin: design, pharmacological and clinical applications. Method. Enzymol. 248, 263-283 (1995).
13. Turner, A.J. & Murphy, L.J. Molecular pharmacology of endothelin converting enzymes. Biochem. Phormacol. 51, 91-102 (1996).
14. Turner, A.J., Murphy, L.J., Medeiros, M.S. & Barnes, K. Endopeptidase-24.11 (neprilysin) and relatives: twenty years on. Adv. Exp. Med. Biol. 389, 141-148 (1996).
15. Turner, A.J. & Tanzawa, K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 11, 355-364 (1997).
16. Hersh, L.B. & Morihara, K. Comparison of subsite specificity of the mammalian neutral endopeptidase-24.11 (enkephalinase) to the bacterial neutral endopeptidase, thermolysin. J. Biol. Chem. 261, 6433-6437 (1986).
17. Pozsgay, M., Michaud, C., Liebman, M. & Orlowski, M. Substrate and inhibitor studies of thermolysin-like neutral metalloendopeptidase from kidney membrane fractions. Comparison with bacterial thermolysin. Biochemistry 25, 1292-1299 (1986).
18. Howell, S., Nalbantoglu, J. & Crine, P. Neutral endopeptidase can hydrolyze β-amyloid(1-40) but shows no effect on β-amyloid precursor protein metabolism. Peptides 16, 647-652 (1994).
19. Nishimura, K. & Hazato, T. Isolation and identification of an endogenous inhibitor of enkephalin-degrading enzymes from bovine spinal cord. Biochem. Biophys. Res. Commun. 194, 713-719 (1993).
20. Orlowski, M. & Wilk, S. Purification and specificity of a membrane-bound metalloendopeptidase from bovine pituitaries. Biochemistry 20, 4942-4950 (1981).
21. Morishima-Kawashima, M. & Ihara, Y. The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblostoma cells. Biochemistry 37, 15247-15253 (1998).
22. Duff, K. et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713 (1996).
23. Ida, N., Masters, C.L. & Beyreuther, K. Rapid cellular uptake of Alzheimer amyloid βA4 peptide by cultured neuroblastoma cells. FEBS Lett. 394, 174-178 (1996).
24. Qiu, W.W. et al. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273, 32730-32738 (1998).
25. Yamin, R. et al. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-β peptide degradation. J. Biol. Chem. 274, 18777-18784 (1999).
26. Scheuner, D. et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864-870 (1996).
27. Games, D. et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523-527 (1995).
28. Hsiao, K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
29. NS(pE), in senile plaques. Neuron 14, 457-466 (1995).
30. Beavis, R.C., Chaudary, T. & Chait, B.T. α-Cyano-4-hydroxy cinematic acid as a matrix for matrix-assisted laser desorption mass spectrometry. Org. Mass Spectrom. 27, 156-158 (1992).
31. Vorm, O., Roepstorff, P. & Mann, M. Improved resolution and very high sensitivity in MALDI TOF of matrix surfaces made by fast evaporation. Anal. Chem. 66, 3281-3287 (1994).
32. Chang, C.D. & Neienhofer, J. Solid-phase synthesis using mild base cleavage of Nα-fluorenylmethyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. Int. J. Pept. Protein Res. 11, 246-249 (1978).
33. Paxinos, G., and Watson, C. The Rat Brain in Stereotaxic Coordinates (San Diego, California: Academic Press, 1986).
34. McDermott, J.R. & Gibson, A.M. Degradation of Alzheimer's β-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem. Res. 22, 49-56 (1997).